

Fibrinopeptide B, human TFA

Cat. No.:	HY-P1493A	
Molecular Formula:	C ₆₈ H ₉₄ F ₃ N ₁₉ O ₂₇	
Molecular Weight:	1666.58	
Sequence:	{Glp}-Gly-Val-Asn-Asp-Asn-Glu-Glu-Gly-Phe-Phe-Ser-Ala-Arg	{Glp}GVNDNEEGFFSAR (TFA salt)
Sequence Shortening:	{Glp}-GVNDNEEGFSAR	
Target:	Others	
Pathway:	Others	
Storage:	Sealed storage, away from moisture	
	Powder	-80°C 2 years
		-20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 1.25 mg/mL (0.75 mM; Need ultrasonic)
In Vivo	1. Add each solvent one by one: PBS Solubility: 2 mg/mL (1.20 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	Fibrinopeptide B, human TFA (FPB,human TFA), human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin ^[1] .
In Vitro	Fibrinopeptide B, human is released from the amino-terminus of the B 3-chains of fibrinogen by thrombin. Fibrinopeptide B, human (hFpB, 10 nM) causes directed cell migration of neutrophils (PMN), and fibroblasts. Fibrinopeptide B, human also possesses potent chemotactic activity relative to human complement (C5a), leukotriene B4 (LTB4), and formyl-methionylleucyl-phenylalanine (fMLP), and for fibroblasts its chemotactic activity is comparable to that of platelet-derived growth factor. However, Fibrinopeptide B, human is not chemotactic for monocytes, and shows no interaction with PMN receptor for C5a, LTB4, or fMLP ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Senior RM, et al. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest. 1986 Mar;77(3):1014-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA